Boc-L-allo-isoleucine

Boc-L-allo-isoleucine is a Boc-protected amino acid building block derived from L-allo-isoleucine, providing a protected N-terminus for controlled peptide assembly. The side chain retains the isoleucine framework while the allo stereochemical relationship at the alpha center supports incorporation into stereochemically defined peptide targets. As a protected amino acid, it is primarily used as a peptide synthesis reagent where the Boc group enables standard protection/deprotection workflows and the free carboxyl functionality can be carried forward into amide bond formation under peptide coupling conditions.

1. Solid-Phase Peptide Synthesis

Boc-L-allo-isoleucine is used by peptide synthesis groups to install an allo-isoleucine residue into peptide sequences during solid-phase peptide synthesis workflows. The Boc-protected amino terminus supports stepwise chain assembly and helps maintain sequence fidelity when building peptides for structure-activity studies, epitope mapping, or stereochemical control in peptide libraries. Researchers commonly select this specific stereochemical amino acid building block when they need allo stereochemistry at the residue level to probe conformational preferences, backbone stereochemical effects, or to match a reference peptide used in downstream binding or stability assays.

2. Stereochemically Defined Peptide Libraries

Boc-L-allo-isoleucine is frequently employed in medicinal chemistry and chemical biology to generate stereochemically defined peptide analogs and libraries where residue-level stereochemistry is a key variable. By using a Boc-protected allo-isoleucine building block, peptide developers can systematically compare peptides that differ at the allo stereocenter while keeping other sequence elements constant, supporting structure-property investigations such as conformational bias and sequence-dependent behavior in assay formats. This reagent is also used in custom peptide manufacturing research settings where reproducible stereochemistry is required for analytical characterization and for consistent downstream conjugation or fragment coupling steps.

3. Pharmaceutical Intermediate Development

Boc-L-allo-isoleucine is used as a protected amino acid intermediate for preparing peptide-based pharmaceutical intermediates and advanced building blocks that retain a Boc-protected amino group for controlled downstream transformations. Process development teams and synthetic chemistry groups incorporate this type of Boc-protected residue into larger coupling schemes to access stereochemically defined amide-containing intermediates used in lead optimization programs, peptide conjugates, or peptidomimetic scaffolds. The Boc protection pattern provides a practical handle for managing orthogonal reactivity across multi-step synthesis sequences, enabling reliable progression from amino acid residue installation to later functionalization steps.

4. Custom Peptide Segment Coupling

Boc-L-allo-isoleucine is applied in solution-phase and fragment coupling approaches when peptide segments or short oligopeptides are assembled with defined stereochemical content. Peptide chemists use Boc-protected allo-isoleucine to prepare residue-containing segments that can be coupled to other protected fragments, supporting the construction of longer targets while maintaining the desired stereochemistry at the allo-isoleucine position. This application is particularly relevant for laboratories that prioritize controlled assembly of stereodefined peptide regions for subsequent purification, analytical verification, and functional testing in chemical biology workflows.

1. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

2. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

3. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

4. High fat diet and GLP-1 drugs induce pancreatic injury in mice

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy